Quhill, Fahd, and Annette Beiderbeck. “Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) Versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema”. Global and Regional Health Technology Assessment 4, no. 1 (July 24, 2017): 155–164. Accessed November 21, 2024. https://journals.aboutscience.eu/index.php/grhta/article/view/391.